SCHEMBL7069149

SCHEMBL7069149

CCCOCc1ccccc1OCCNC(=O)c1ccc2nc(C(C)c3nc4ccccc4[nH]3)n(C)c2c1

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TPSAB1 Q15661 3/20 0.39
TPSD1 Q9BZJ3 3/20 0.39
TPSG1 Q9NRR2 3/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
HPSE Q9Y251 1/20 0.38
LMNA P02545 2/20 0.37
POLB P06746 2/20 0.36
TDP1 Q9NUW8 1/20 0.36
ACSS2 Q9NR19 3/20 0.36
TSHR P16473 2/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
MAPK10 P53779 1/20 0.36
HTT P42858 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
MAPT P10636 2/20 0.36
HPGD P15428 1/20 0.36
ALDH1A1 P00352 1/20 0.36
PAX8 Q06710 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7071846 0.96 TPSAB1 (0.39) TPSAB1TPSD1TPSG1L3MBTL1LMNA
SCHEMBL7073278 0.94 L3MBTL1 (0.41) TPSAB1TPSD1TPSG1L3MBTL1LMNA
SCHEMBL7075080 0.94 TPSAB1 (0.39) TPSAB1TPSD1TPSG1L3MBTL1LMNA
SCHEMBL7073880 0.93 L3MBTL1 (0.42) TPSAB1TPSD1TPSG1L3MBTL1LMNA
SCHEMBL7075305 0.92 TPSAB1 (0.40) TPSAB1TPSD1TPSG1L3MBTL1HPSE
SCHEMBL7070278 0.90 MEN1 (0.47) TPSAB1TPSD1TPSG1L3MBTL1HPSE
SCHEMBL7073523 0.89 TPSAB1 (0.39) TPSAB1TPSD1TPSG1LMNAPOLB
SCHEMBL7072276 0.88 NPC1 (0.44) TPSAB1TPSD1TPSG1L3MBTL1ACSS2
SCHEMBL7073363 0.88 L3MBTL1 (0.50) TPSAB1TPSD1TPSG1L3MBTL1LMNA
SCHEMBL7068373 0.88 TPSAB1 (0.39) TPSAB1TPSD1TPSG1L3MBTL1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030212120-A1 Compositions comprising a substituted benzimidazole useful for treating immunomediated inflammatory disorders AXYS PHARMACEUTICALS, INC. (US) 2003-11-13 US disclosed
US-6562854-B2 Antiinflammatory agents; respiratory system disorders AXYS PHARMACEUTICALS, INC. 2003-05-13 US disclosed
US-20010053779-A1 Novel compounds and compositions for treating diseases asociated with protease activity Celera Corporation 2001-12-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010053779-A1 Novel compounds and compositions for treating diseases asociated with protease activity CMA1, CPA3, TPSG1 TPSAB1 5/4885TPSD1 6/4885TPSG1 3/4885
US-20030212120-A1 Compositions comprising a substituted benzimidazole useful for treating immunomediated inflammatory disorders CMA1, TPSG1, TPSD1 TPSAB1 5/4885TPSD1 3/4885TPSG1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.